Product Data Sheet

IRAK4-IN-7

 Cat. No.:
 HY-109585

 CAS No.:
 1801343-74-7

 Molecular Formula:
 $C_{21}H_{19}N_7O_3$

Molecular Weight: 417.42
Target: IRAK

Pathway: Immunology/Inflammation

Storage: Powder -20°C 3 years

4°C 2 years

In solvent -80°C 2 years

-20°C 1 year

SOLVENT & SOLUBILITY

In Vitro

DMSO: 13.89 mg/mL (33.28 mM; Need ultrasonic)

	Solvent Mass Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	2.3957 mL	11.9783 mL	23.9567 mL
	5 mM	0.4791 mL	2.3957 mL	4.7913 mL
	10 mM	0.2396 mL	1.1978 mL	2.3957 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: \geq 1.39 mg/mL (3.33 mM); Clear solution

BIOLOGICAL ACTIVITY

Description	IRAK4-IN-7 is a selective, potent and orally active interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, extracted from patent WO2015104688 (example 1). IRAK4-IN-7 has the potential for cancer and inflammatory diseases treatment ^[1] .
IC ₅₀ & Target	IRAK4 (IC ₅₀)
In Vivo	IRAK4-IN-7 has anti-cancer and anti-inflammatory activities, it can be used for cancer and inflammatory diseases treatment [1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

l]. Venkateshwar Rao GUMMA	DI, et al. Bicyclic heterocyc	clyl derivatives as irak4 inhibitors. '	NO2015104688A1.	
	Caution: Product has	not been fully validated for m	edical applications. For research use on	ly.
	Tel: 609-228-6898 Address	Fax: 609-228-5909 : 1 Deer Park Dr, Suite Q, Monm	E-mail: tech@MedChemExpress.co nouth Junction, NJ 08852, USA	m

Page 2 of 2 www.MedChemExpress.com